Business Context and Reporting Period
This Form 8-K Current Report was filed by Artelo Biosciences, Inc. on August 30, 2019. The report discloses an amendment to the employment agreement with Mr. Gregory D. Gorgas, President and CEO, effective as of June 20, 2019. The Company is incorporated in Nevada and identifies as an emerging growth company.
Key Financial Metrics
The filing does not provide general financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data contained in this report is limited to the specific compensation terms of the CEO's employment agreement:
- Base Salary: $396,000 per year.
- Target Bonus: Up to 50% of base salary ($198,000) contingent on performance objectives.
- Equity Grant: Option to purchase 75,000 shares of common stock at an exercise price of $1.99 per share.
- Life Insurance: Company pays premiums for coverage up to $1,000,000.
Material Changes
The primary material change reported is the execution of an amended and restated employment agreement with Mr. Gorgas. This agreement supersedes the previous agreement dated April 3, 2017. The new terms establish a fixed base salary, a defined bonus structure, and a new equity grant with a 48-month vesting schedule commencing August 29, 2019.
Outlook, Risks, and Contingencies
Severance and Change of Control: The agreement outlines significant contingent liabilities in the event of termination without cause or for "good reason":
- Change of Control Window (3 months prior to 12 months after): Entitles Mr. Gorgas to 12 months of base salary, prorated target bonus, 12 months of COBRA, and 100% accelerated vesting of all equity awards.
- Outside Change of Control Window: Entitles Mr. Gorgas to 12 months of monthly base salary payments, prorated target bonus, 12 months of COBRA, and accelerated vesting of time-based equity and satisfied performance-based equity.
Tax Contingency: The agreement includes a "gross-up" provision to ensure Mr. Gorgas receives the greater of the full severance amount or the amount reduced to avoid excise taxes under Section 4999 of the Internal Revenue Code.
Investor Verification Checklist
- Verify the total number of shares outstanding and the dilution impact of the 75,000 new options granted.
- Review the Company's cash position to assess the ability to fund the $396,000 annual salary and potential severance obligations.
- Confirm the specific performance objectives required to trigger the 50% target bonus, as these are determined by the Board.
- Monitor future filings (Form 10-K) for the full text of the Employment Agreement referenced in this report.